Labcorp Holdings Inc. Common Stock (LH) is currently showing a bullish headline tone with a mixed / range backdrop. The latest news flow is being framed here as context rather than prediction, so beginners can quickly see whether headlines are helping, hurting, or complicating the chart story. Earnings tone is currently no clear earnings read.
HEADLINE TAKE: Higher-value headlines lean meaningfully positive, with stronger signals around growth, upgrades, guidance, or demand.
Change stock
Search another ticker to view its latest news page.
Full chart, indicators and drawing tools on TradingView. Move to Platforms when you are ready to act.
MyStockHarbor.com
NEWS SCORE
87/100
Bullish
Bearish
Neutral
Bullish
Earnings Tone
78
Good based on actual EPS/revenue
Confidence
High
Headline depth
Last Price
$271.99
Trend Context
Mixed / range
Latest briefing
What's happening with LH
prnewswire.com9 Jul 2026
Labcorp Declares Quarterly Dividend
BURLINGTON, N.C., July 9, 2026 /PRNewswire/ -- Labcorp Holdings Inc. (NYSE: LH), a global leader of innovative and comprehensive laboratory services, announced today that its Board of Directors has declared a cash dividend of $0.72 per share of common stock.
Article excerpt provided by the FMP news feed. AI is used only for the optional "Why this matters" read.Read full article ↗
prnewswire.com30 Jun 2026
Labcorp to Announce Second Quarter 2026 Financial Results on July 30, 2026
BURLINGTON, N.C., June 30, 2026 /PRNewswire/ -- Labcorp Holdings Inc. (NYSE: LH), a global leader of innovative and comprehensive laboratory services, will release its financial results for the second quarter of 2026 before the market opens on Thursday, July 30, 2026.
Article excerpt provided by the FMP news feed. AI is used only for the optional "Why this matters" read.Read full article ↗
prnewswire.com22 Jun 2026
Labcorp Announces Nationwide Availability of ColoSense®, the First FDA-Approved RNA-Based At-Home Colorectal Cancer Screening Test
First FDA-approved, at-home screening test that uses RNA technology to detect biomarkers associated with colorectal cancer and advanced adenomas Designed to reduce common barriers to at-home screening with a cleaner, simplified collection experience that minimizes sample handling Meets screening guidelines from the American Cancer Society (ACS) and National Comprehensive Cancer Network (NCCN) BURLINGTON, N.C. and ST. LOUIS, June 22, 2026 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehe…
Article excerpt provided by the FMP news feed. AI is used only for the optional "Why this matters" read.Read full article ↗
Older updates drop into a lighter feed
seekingalpha.com
3 Jun 2026
Labcorp Holdings Inc. (LH) Presents at Jefferies Global Healthcare Conference 2026 Transcript